NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 239 filers reported holding NEKTAR THERAPEUTICS in Q2 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,646,873 | -30.7% | 6,123,024 | -33.1% | 0.00% | -20.0% |
| Q2 2023 | $5,264,415 | +126.8% | 9,152,321 | +177.2% | 0.01% | +150.0% |
| Q1 2023 | $2,320,737 | -9.0% | 3,301,661 | +192.7% | 0.00% | -33.3% |
| Q4 2022 | $2,549,090 | +17.4% | 1,127,916 | +66.1% | 0.00% | 0.0% |
| Q3 2022 | $2,172,000 | +3.7% | 678,921 | +23.2% | 0.00% | +50.0% |
| Q2 2022 | $2,094,000 | -39.5% | 550,956 | -14.1% | 0.00% | -33.3% |
| Q1 2022 | $3,459,000 | -33.9% | 641,618 | +65.7% | 0.00% | -25.0% |
| Q4 2021 | $5,232,000 | -29.9% | 387,233 | -6.8% | 0.00% | -42.9% |
| Q3 2021 | $7,460,000 | +33.4% | 415,399 | +27.5% | 0.01% | +40.0% |
| Q2 2021 | $5,592,000 | -32.6% | 325,885 | -21.5% | 0.01% | -37.5% |
| Q1 2021 | $8,299,000 | -51.4% | 414,911 | -58.7% | 0.01% | -46.7% |
| Q4 2020 | $17,078,000 | +84.4% | 1,004,514 | +80.0% | 0.02% | +66.7% |
| Q3 2020 | $9,259,000 | -26.1% | 558,119 | +3.2% | 0.01% | -35.7% |
| Q2 2020 | $12,523,000 | +2019.0% | 540,727 | +1531.8% | 0.01% | – |
| Q1 2020 | $591,000 | -82.7% | 33,137 | -79.0% | 0.00% | -100.0% |
| Q4 2019 | $3,412,000 | +3.2% | 158,069 | -12.9% | 0.00% | -25.0% |
| Q3 2019 | $3,306,000 | -75.6% | 181,484 | -52.3% | 0.00% | -76.5% |
| Q2 2019 | $13,535,000 | -68.0% | 380,419 | -69.8% | 0.02% | -69.1% |
| Q1 2019 | $42,276,000 | +39.1% | 1,258,221 | +36.1% | 0.06% | +31.0% |
| Q4 2018 | $30,392,000 | +103.2% | 924,633 | +276.8% | 0.04% | +133.3% |
| Q3 2018 | $14,960,000 | -30.2% | 245,403 | -44.1% | 0.02% | -35.7% |
| Q2 2018 | $21,421,000 | -75.0% | 438,689 | -45.6% | 0.03% | -76.1% |
| Q1 2018 | $85,685,000 | +4867.2% | 806,367 | +2690.9% | 0.12% | +5750.0% |
| Q4 2017 | $1,725,000 | +232.4% | 28,893 | +33.5% | 0.00% | +100.0% |
| Q3 2017 | $519,000 | -80.5% | 21,642 | -84.1% | 0.00% | -75.0% |
| Q2 2017 | $2,655,000 | -13.7% | 135,798 | +3.5% | 0.00% | -20.0% |
| Q1 2017 | $3,078,000 | +30.8% | 131,147 | -31.6% | 0.01% | +25.0% |
| Q4 2016 | $2,353,000 | +36.2% | 191,793 | +90.7% | 0.00% | +33.3% |
| Q3 2016 | $1,728,000 | -23.2% | 100,570 | -36.4% | 0.00% | -25.0% |
| Q2 2016 | $2,249,000 | -77.7% | 158,045 | -78.5% | 0.00% | -77.8% |
| Q1 2016 | $10,095,000 | +62.2% | 734,186 | +98.8% | 0.02% | +100.0% |
| Q4 2015 | $6,223,000 | -5.4% | 369,351 | -29.7% | 0.01% | -10.0% |
| Q2 2015 | $6,576,000 | -20.2% | 525,681 | -29.8% | 0.01% | -23.1% |
| Q1 2015 | $8,236,000 | +33.4% | 748,678 | +87.9% | 0.01% | +62.5% |
| Q4 2014 | $6,176,000 | +1291.0% | 398,426 | +983.0% | 0.01% | +700.0% |
| Q3 2014 | $444,000 | -36.3% | 36,789 | -32.3% | 0.00% | 0.0% |
| Q2 2014 | $697,000 | -62.0% | 54,359 | -64.1% | 0.00% | -66.7% |
| Q1 2014 | $1,836,000 | -75.3% | 151,486 | -76.9% | 0.00% | -70.0% |
| Q4 2013 | $7,439,000 | -30.9% | 655,393 | -36.4% | 0.01% | -41.2% |
| Q3 2013 | $10,760,000 | +93.8% | 1,029,738 | +114.2% | 0.02% | +70.0% |
| Q2 2013 | $5,553,000 | – | 480,733 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rhenman & Partners Asset Management AB | 508,000 | $6,132,000 | 1.80% |
| Bodri Capital Management, LLC | 250,000 | $3,018,000 | 1.46% |
| Granahan Investment Management | 3,442,980 | $41,557,000 | 1.28% |
| TIRSCHWELL & LOEWY INC | 603,441 | $7,284,000 | 1.22% |
| NEA Management Company, LLC | 1,825,600 | $22,035,000 | 1.12% |
| Cormorant Asset Management, LP | 450,000 | $5,432,000 | 1.12% |
| HARVEY CAPITAL MANAGEMENT INC | 221,750 | $2,676,000 | 1.05% |
| Cheyne Capital Management (UK) LLP | 229,577 | $2,772,000 | 0.99% |
| Artal Group S.A. | 1,650,000 | $19,916,000 | 0.73% |
| FIC CAPITAL INC | 147,293 | $1,778,000 | 0.71% |